China Biopsy Devices Market Trends & Summary

The China biopsy devices market is entering a transformative era fueled by medical innovation, rising healthcare demand, and robust government investment. According to Renub Research, the market is expected to surge to US$ 1,131.98 million by 2033, rising sharply from US$ 612.62 million in 2024. With a CAGR of 7.06% during 2025–2033, China is rapidly emerging as one of the world’s most dynamic markets for minimally invasive diagnostic technologies.

Behind this growth lies a convergence of critical factors: a rising cancer burden, greater awareness of early disease detection, significant investment in healthcare modernization, and the widespread adoption of advanced biopsy systems. As China continues prioritizing early intervention and accurate diagnostics, biopsy devices will play an increasingly essential role in patient care—especially in oncology, where precision and timely diagnosis can dramatically improve treatment outcomes.

This comprehensive market overview explores the forces driving growth, the challenges that remain, and the opportunities unfolding across product segments, technologies, and healthcare institutions.

Download Free Sample Report

China Biopsy Devices Industry Overview

Biopsy devices represent some of the most essential tools in modern medicine. These instruments—ranging from needle-based guns and forceps to vacuum-assisted and imaging-guided systems—enable clinicians to extract tissue samples for diagnostic evaluation. The ability to detect abnormalities early, particularly in cancers of the breast, lung, prostate, and liver, makes biopsy devices indispensable to effective healthcare.

In China, demand for these technologies has intensified significantly. Cancer continues to be a major public health concern due to shifting lifestyles, industrialization, aging demographics, and persistent environmental challenges. As cases rise, hospitals and diagnostic centers across the country have adopted advanced biopsy solutions promoting precise, minimally invasive sampling.

Innovations such as ultrasound-guided, stereotactic, and robotic biopsy systems have expanded access to accurate diagnostics even in complex cases. This shift, combined with public health initiatives supporting early detection programs, is accelerating the adoption of biopsy devices throughout China’s rapidly evolving healthcare ecosystem.

Key Growth Drivers for the China Biopsy Devices Market

1. Rising Prevalence of Cancer

The most influential force behind China’s growing biopsy device market is the alarming rise in cancer cases. According to national statistics, China recorded approximately 4.82 million new cancer cases and 2.57 million cancer-related deaths in 2022. Lung, colorectal, thyroid, liver, and stomach cancers collectively accounted for more than 57% of all new diagnoses.

This trend highlights an urgent need for early detection tools. Biopsy devices—especially minimally invasive and imaging-guided solutions—have become the frontline in diagnosing cancers at earlier, more treatable stages. As public health campaigns intensify and screening programs expand, demand for reliable biopsy instruments is expected to grow exponentially.

2. Breakthroughs in Biopsy Technologies

Technological innovation is revolutionizing biopsy procedures in China. Advances such as real-time ultrasound guidance, high-precision robotic systems, and minimally invasive devices are improving biopsy accuracy while enhancing patient comfort.

Ultrasound-guided systems reduce procedure time and enable clinicians to sample tissue with pinpoint precision. Robotic-assisted biopsy platforms enhance dexterity and navigation, allowing practitioners to reach difficult anatomies safely. Even the introduction of vacuum-assisted technologies has transformed breast cancer diagnostics with superior tissue yield and reduced patient discomfort.

A notable milestone occurred in March 2024, when Intuitive Surgical received regulatory approval in China to commercialize its Ion robotic system—further advancing the landscape for precision biopsy solutions.

As hospitals and private diagnostic centers strive to improve diagnostic outcomes, these advanced devices are becoming indispensable.

3. Expansion of China’s Healthcare Infrastructure

China’s healthcare modernization is reshaping access to diagnostic technologies. Massive investments in high-tech hospitals, imaging centers, and rural healthcare expansion reflect the government’s ambition to elevate national healthcare standards.

In September 2024, China’s Ministry of Commerce announced policy changes easing restrictions on foreign-owned hospitals in major cities like Beijing and Shanghai. This is expected to fast-track the adoption of world-class diagnostic and biopsy equipment in both public and private sector facilities.

As advanced imaging systems and trained specialists become more widely available, biopsy devices—especially CT-, MRI-, and ultrasound-guided systems—will see accelerated deployment across the country.

Challenges Impacting Market Growth

1. High Cost of Advanced Biopsy Technologies

Despite progress, financial constraints remain a barrier to widespread adoption. Advanced robotic and imaging-guided biopsy devices require significant investment. Many hospitals—particularly in smaller cities and rural provinces—struggle to afford these high-end systems, limiting their ability to offer state-of-the-art diagnostic services.

The urban–rural healthcare gap remains a major challenge, restricting equitable access to early cancer detection tools across China.

2. Limited Availability of Skilled Professionals

Operating modern biopsy systems requires specialized expertise that is unevenly distributed across the country. Rural areas face shortages of trained radiologists, oncologists, and technicians adept at using advanced biopsy devices.

Insufficient training and inadequate staffing hinder the full utilization of these technologies. As China continues expanding its diagnostic capacity, investment in workforce training will be crucial to maximizing the benefits of biopsy innovations.

Segment Insights Across China’s Biopsy Devices Market

China Needle-Based Guns Biopsy Devices Market

Needle-based biopsy guns remain one of the fastest-growing product categories. Their minimally invasive nature, combined with high precision and compatibility with advanced imaging systems, makes them ideal for diagnosing cancers in the lungs, liver, breasts, and other vital organs.

Growing awareness of early screening—as well as increasing adoption within both public and private healthcare facilities—continues to fuel rapid expansion in this segment.

China Breast Biopsy Devices Market

Breast cancer remains a rising concern in China, propelling demand for advanced biopsy technologies. Core needle biopsy systems and vacuum-assisted devices are seeing strong adoption due to their high diagnostic accuracy and patient-friendly design.

In February 2024, Hologic launched its Selenia Dimensions 3D Mammography System in China, integrating enhanced imaging and biopsy capabilities to improve breast cancer detection. As awareness and screening programs expand, demand for precision breast biopsy devices will continue to soar.

China Lung Biopsy Devices Market

Rapid industrialization, high pollution levels, and widespread smoking habits have made lung cancer one of China’s most prevalent and deadly diseases. The result: surging demand for advanced lung biopsy technologies.

CT-guided biopsy systems are gaining prominence due to their ability to detect deep-seated pulmonary lesions. These tools significantly improve diagnostic accuracy, making them indispensable in lung cancer care pathways.

China CT Scan Biopsy Devices Market

CT-guided biopsy devices are becoming a cornerstone of modern diagnostics in China. Their ability to precisely target internal abnormalities—especially in organs located deep within the body—has made them essential for detecting complex cancers and lesions.

As clinicians increasingly rely on CT imaging for minimally invasive interventions, this segment will continue experiencing robust growth.

China MRI-Guided Biopsy Devices Market

MRI-guided biopsy solutions are witnessing accelerating demand due to the modality’s unparalleled ability to visualize soft tissues with high precision. These devices are especially valuable for breast and brain biopsies, where detailed imaging is critical.

With technological advancements enabling faster, more comfortable MRI procedures, adoption is rising across major hospitals and specialized cancer centers.

China Biopsy Devices in Diagnostic & Imaging Centers

Diagnostic and imaging centers are playing an increasingly pivotal role in expanding access to advanced biopsy procedures. Equipped with modern imaging technologies and staffed by trained specialists, these centers help bridge the gap between urban and rural healthcare capacities.

Their rapid expansion is significantly contributing to market growth by offering faster, more accurate diagnostic services to a wider population.

Market Segmentation Summary

Product Segments (5 Viewpoints)

Needle-Based Guns

Biopsy Guidance Systems

Biopsy Needles

Biopsy Forceps

Others

Application Segments (6 Viewpoints)

Breast

Lung

Prostate

Liver

Gastroenterology

Others

Technology Segments (5 Viewpoints)

CT Scan

Stereotactic Guided

Ultrasound Guided

MRI Guided

Others

End Users (3 Viewpoints)

Hospitals

Diagnostic & Imaging Centers

Others

Key Companies Profiled

(Overview • Recent Developments • Revenue Analysis)

Cardinal Health, Inc.

Hologic, Inc.

Danaher Corporation

Becton, Dickinson and Company

Boston Scientific Corporation

Medtronic plc

Olympus Corporation

CONMED Corporation

Final Thoughts

The China biopsy devices market is undergoing a period of extraordinary growth. With cancer rates rising sharply, early detection has become a national priority, and advanced biopsy technologies are at the heart of this movement. Significant investments in healthcare modernization—paired with groundbreaking diagnostic innovations—are enabling China to rapidly expand access to precise and minimally invasive cancer diagnostics.

Yet challenges remain. High equipment costs and uneven distribution of medical expertise may hinder equitable access across rural and underdeveloped regions. Addressing these gaps through workforce development, targeted funding, and technology partnerships will be critical to sustaining long-term progress.

As China continues reshaping its healthcare landscape, the biopsy devices market is set to play an essential role in enhancing patient outcomes and transforming diagnostic care for millions. With strong momentum and continued innovation, the journey ahead holds promising opportunities for stakeholders across the medical device, oncology, and imaging sectors.